Peer-reviewed veterinary case report
Chemotherapy with multiple drugs works better than single drug
By Simon, Daniela et al.·Published in Journal of the American Veterinary Medical Association·2008·Department of Small Animal Medicine and Surgery, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A group of 114 dogs with lymphoma (a type of cancer) was treated with either a combination of several chemotherapy drugs or just one drug, doxorubicin. The results showed that 73% of dogs on the multi-drug treatment went into complete remission, compared to 52% on the single-drug treatment. However, there was no significant difference in how long the dogs stayed in remission or how long they lived after treatment. Some dogs on the multi-drug treatment experienced more vomiting, but overall, both treatment methods had similar side effects.
People also search for: dog lymphoma treatment options · chemotherapy for dogs with cancer · doxorubicin side effects in dogs
Abstract
OBJECTIVE: To compare response rates and remission and survival times in dogs with lymphoma treated with a continuous, multiagent, doxorubicin-based chemotherapeutic protocol or with a short-term single-agent protocol incorporating doxorubicin. DESIGN: Nonrandomized controlled clinical trial. ANIMALS: 114 dogs with lymphoma. PROCEDURES: Dogs were treated with a chemotherapeutic protocol consisting of L-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate, and prednisolone (n=87) or doxorubicin alone (27). RESULTS: 63 of 86 (73%) dogs treated with the multiagent protocol (data on response was unavailable for 1 dog) and 14 of 27 (52%) dogs treated with the single-agent protocol had a complete remission. Dogs with lymphoma classified as substage<or=and dogs with a high BUN concentration at the time of initial diagnosis were significantly less likely to have a complete remission. No significant difference in remission or survival time could be demonstrated between treatment groups. Incidence of hematologic and gastrointestinal tract toxicoses did not differ between treatment groups, with the exception that vomiting was more common among dogs treated with the multiagent protocol. CONCLUSIONS AND CLINICAL RELEVANCE: In this population of dogs, we were not able to identify any significant difference in remission or survival times between dogs with lymphoma treated with a continuous, multiagent chemotherapeutic protocol and dogs treated with a short-term single-agent protocol involving doxorubicin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18341445/